相关实验视频

Updated: Sep 9, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

用于治疗全身性红斑狼的抗人类TLR7抗体

Ryutaro Fukui^1,2,3, Yusuke Murakami^1,4, Atsuo Kanno¹

¹Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

International immunology

|September 5, 2025

概括

托尔类受体7 (TLR7) 在全身性红斑狼 (SLE) 中起着关键作用. 一种新的人性化抗体,DS-7011a,有效抑制TLR7反应,显示出作为一种新型SLE治疗的潜力.

科学领域:

免疫学
自体免疫性
分子生物学

背景情况:

收费类受体7 (TLR7) 感知单链RNA (ssRNA),与系统性红斑狼 (SLE) 等自身免疫性疾病有关.
虽然TLR7抗剂在小鼠模型中表现有前途,但人类TLR7/8对SLE的反应不太清楚.
在不同数据集中,人类SLE患者的TLR7基因表达始终升高.

研究的目的:

研究TLR7在人类SLE发病过程中的作用.
开发和描述一种针对人类TLR7的新型抑制单克隆抗体 (mAb).
评估人类化mAb的治疗潜力,DS-7011a,用于SLE治疗.

主要方法:

对SLE中TLR7和TLR8签名的公共基因表达数据库的分析.
抗人类TLR7单克隆抗体 (mAbs) 的产生.
人体免疫细胞 (pDC,B细胞) 中DS-7011a的抑制活性及其细胞吸收的特征.

主要成果:

在人类SLE数据集中,TLR7基因特征得分明显高于TLR8.
人性化的mAb DS-7011a在人体血细胞树突细胞和B细胞中强烈抑制了TLR7介导的反应.
在关键的免疫细胞中,DS-7011a表现出TLR7依赖的内化和积累.

结论:

TLR7在人类SLE发病过程中起着重要作用,可能比TLR8更重要.
DS-7011a是人类TLR7反应的强有力的抑制剂.
DS-7011a是治疗SLE的前临床候选药物.

关键词:

抗体药物自体免疫性基因签名人性化抗体

更多相关视频

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...